COMPANY OVERVIEW
Insilico Medicine, with headquarters in Hong Kong and Abu Dhabi (AI hub), is a clinical-stage generative AI company pioneering end-to-end AI-powered drug discovery. Founded in 2014 by Dr. Alex Zhavoronkov, their Pharma.AI platform has produced multiple clinical-stage candidates, including INS018_055—the first AI-designed drug for a novel AI-discovered target to enter Phase II trials.
PHARMA.AI PLATFORM
- PandaOmics (Biology42): AI target discovery using multi-omics, text mining, and knowledge graphs
- Chemistry42: Generative chemistry for de novo molecule design with ADMET optimization
- inClinico: Clinical trial outcome prediction using historical data and patient features
- End-to-End: Novel target to preclinical candidate in ~18 months (vs. 4-6 years traditional)
CLINICAL MILESTONES
- INS018_055: First AI-designed drug for AI-discovered target in Phase II (idiopathic pulmonary fibrosis)
- ISM001-055: Anti-fibrotic candidate from COVID-19 pandemic rapid response
- 35+ Programs: Oncology, immunology, CNS, fibrosis therapeutic areas
- $2.6B Partnership Value: Sanofi, Fosun Pharma, Exelixis collaborations
SPEED ADVANTAGE
Insilico demonstrated AI's drug discovery potential by designing INS018_055 from target identification to Phase I in under 30 months—a process typically requiring 6+ years. This compressed timeline reduces costs from ~$500M to under $50M for preclinical development, fundamentally changing pharmaceutical R&D economics.